Market Research Logo

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

The global market for prostate cancer products reached nearly $47.2 billion in 2016 and should reach nearly $65.1 billion in 2021, with a compound annual growth rate (CAGR) of 6.6%.

Report Includes
An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection and diagnosis, and anticancer agents
Analyses of global market trends, with data from 2012, 2016, and projections of compound annual growth rates (CAGRs) through 2021
Discussion of risk factors, natural history, epidemiology, and the genetics of prostate cancer
Examinations of prostate-specific antigen (PSA) screening, including the causes of PSA changes, PSA thresholds, and controversies over the screening
Coverage of emerging therapies, including combination therapy, therapeutic vaccines, inhibitors of kinase signaling pathways, proteasome inhibitors, angiogenesis inhibitors, and immunotherapeutic agents
Evaluation of prostate cancer treatment products by geography, race, and category
Breakdown of the industry structure, including market shares, trends in price and price performance, and factors influencing demand
Comprehensive company profiles of major players in the field.


Report Scope
The scope of this study is testing, screening technology and also therapeutics markets for prostate cancer. The report also includes the regulatory environment, current technologies, new technologies, prostate cancer incidence, market projections and market share, along with latest trends and new developments.

Screening for diagnosis, therapy via drug, surgery or radiation is measured and broken down by PSA testing, digital rectal exam (DRE), prostate biopsy, hormone therapy, chemotherapy, immunotherapy, external beam radiation therapy (EBRT), prostatectomy and brachytherapy.

Chapter 1 Introduction
Introduction
Study goals and objectives
Reasons for doing this study
Intended audience
Scope of report
Information sources
Methodology
Geographic breakdown
Analyst's credentials
Related BCC Research reports
Chapter 2 Summary and Highlights
Summary and highlights
Chapter 3 Overview
Overview
Introduction
U.S. Preventive Services Task Force recommendations
Biology of prostate cancer
Prostate gland
Prostate gland function
Growth of the prostate gland
Types of prostate cancer
Precancerous conditions of the prostate
Prostate cancer development and aging
Mechanisms of disease development pathophysiology
Family history
Environmental factors
Epidemiology and risk factors
Hormones
Growth factors
Genetics
Molecular mechanisms of prostate cancer
The Androgen Receptors
PTEN
p53
GSTP genes
Prostate-specific antigen
Caveolin-1
EMSY
AMACR
KLF6
NBS1
CHEK2
Mismatch repair genes
HOXB13 protein coding gene
BRCA1 and BRCA2
Hereditary prostate cancer
Prostate cancer prevention and treatment
Conclusion
Chapter 4 Prostate Cancer information
Prostate cancer information
Detection and diagnosis
Diagnosis
Screening, diagnosis and management of prostate cancer
Recommendations for prostate cancer early detection
Guidelines for prostate cancer screening
Prostate cancer screening guidelines: historical perspective
Prostate cancer screening
Staging and grading of prostate cancer
Diagnostic biopsy
Test for metastasis
New methods in development
Imaging strategies for diagnosis of prostate cancer
Prostate cancer prognosis and outcomes predictions
Conclusion
Chapter 5 Prostate Cancer Screening and Diagnosis
Prostate cancer screening and diagnosis
Prostate cancer screening, diagnosis and prognosis
Screening controversies
PSA tests
Digital rectal exam
Prostate ultrasound
Imaging technologies for prostate cancer
Conclusion
Chapter 6 Prostate Cancer: Therapeutic Interventions
Prostate cancer: therapeutic interventions
Treatment plan
Treatment options
Treatment strategies for prostate cancer by stage
Surgery
Secondary therapy
Radiotherapy
Interstitial brachytherapy for low-risk cancers
External beam radiotherapy
Combined radiation therapy
Cryotherapy
High-intensity focused ultrasound
Focal ablation
Hormone therapy
Androgen deprivation, an adjuvant therapy
Chemoprevention and chemotherapy
Immunotherapy/therapeutic vaccines
Vascular-targeted photodymanic therapy
Nutritional therapy
Erectile dysfunction
Emerging therapies
Conclusion
Chapter 7 Prostate Cancer Therapeutics in the Global Market
Prostate cancer therapeutics in the global market
What is cancer?
Drugs approved for prostate cancer
Drug descriptions
Other therapeutic agents
Chapter 8 Global Burden of Cancer
Global burden of cancer
Global prostate cancer statistics
Prostate cancer mortality
Prostate cancer burden globally
Prostate cancer in the United States
Prostate cancer and Canada
Prostate cancer and Europe
Prostate cancer in Asia
Other nations
Conclusion
Chapter 9 Prostate Cancer and Diagnostic Market
Prostate cancer and diagnostic market
Screening tests
PSA testing: yes or no controversy
Prostate cancer market size
Prostate cancer screening market
DRE market
Market for prostate biopsy
Prostate cancer diagnostic imaging market
Imaging market outlook
Chapter 10 Prostate Cancer Treatment Market
Prostate cancer treatment market
Treatment plan for prostate cancer
Treatment costs associated with prostate cancer
Prostate cancer therapies: three leading prostate cancer therapies
Prostate cancer surgery and radiotherapy market
Prostate cancer surgical device market
Radiotherapy market
Brachytherapy market
Ultrasound market
Prostatectomy market
Urological market
HIFU in the United States
Robotic prostatectomy market
Prostate cancer device market in Asia and Latin America
Chapter 11 Prostate Cancer Drugs Market
Prostate cancer drugs market
Global oncology therapeutics market
New approaches to treat prostate cancer
Cytotoxic therapies market
Prostate cancer incidence and impact on market
Current prostate cancer therapeutics
Generic prostate cancer drugs
Newer therapies on the market
Recent drug approvals and market
Prostate cancer: therapeutic drugs landscape
Market for chemotherapy
Market for chemotherapy drugs for prostate cancer
Market for hormone therapy
Hormone therapy drugs
Market for immunotherapy
Prostate cancer care market
Conclusion
Chapter 12 Emerging Prostate Cancer Drugs
Emerging prostate cancer drugs
Emerging products
Cabozantinib
Xgeva
Custirsen
Tasquinimod
Sprycel
TAK-700
Prostvac
Alpharadin
DCVax-Prostate
Not approved drugs
Avodart
Conclusion
Chapter 13 Prostate Cancer Patents
Prostate cancer patents
Prostate cancer drug patents expiry
Conclusion
Chapter 14 Selected Company Profiles
Selected company profiles
Abbott Laboratories
Active Biotech AB
Algeta
Amgen
Astellas Pharma US
AstraZeneca
Atrix Laboratories
Bavarian Nordic A/S
Bayer HealthCare Pharmaceuticals
Bristol-Myers Squibb
C.R. Bard
CZ BioMed Corp.
Dendreon Corp.
DiagnoCure
Exelixis
Exosome Diagnostics
GE Healthcare
Genomic Health
GlaxoSmithKline
Hologic
Intuitive Surgical
Johnson & Johnson
Medivation
Metamark
Millennium Pharmaceuticals
Myriad Genetics
Northwest Biotherapeutics
Oncogenex
Opko Health
Pfizer
Sanofi
Siemens AG
Spectrum Pharmaceuticals
Varian Medical Systems
Appendix References and End Notes
References and end notes
References
End notes
Lists of Tables and Figures
About BCC Research
About BCC Research
Conditions of purchase
Report Subscriptions
Custom Analyses

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report